Changzhou Qianhong Bio-pharma 千红制药
13 significant filings since 31 May 2026: 7 on share issue and 6 on equity incentive. The latest, on 8 Aug 2026: 千红制药：2025年员工持股计划（草案）（修订稿）.
自 31 May 2026 起有 13 份重大公告：share issue 7 份、equity incentive 6 份。最新一份（8 Aug 2026）：千红制药：2025年员工持股计划（草案）（修订稿）。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 26 Oct 2018 | 民生证券 | 肖汉山,袁中平 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东海证券 | 杜永宏 | Buy 买入 | 14 Aug 2026 | 2 | — |
| 东吴证券 | 朱国广 | Buy 买入 | 1 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。